| By Larry Lucas | SACOBSERVER.COM
WIRE SERVICES (NNPA) - A new year
is upon us, and with it comes the expectation and promise
of new beginnings. Nowhere is this more evident than in our
nation’s capital. As Barack Obama takes office, he and
his advisers are sure to face a host of challenges, not the
least of which is reforming our nation’s healthcare
system.
Our healthcare system has clear strengths, but faces sobering
challenges. Rising healthcare costs and premiums are making
health insurance coverage unaffordable for an increasing number
of businesses and families. In fact, more than 20 percent
of African Americans are living without health insurance,
according to a recent study from the Kaiser Family Foundation.
The serious economic downturn is also taking a toll: A one
percent rise in the nation's unemployment rate is projected
to increase the number of uninsured by 1.1 million people,
according to Kaiser. During the last year, the unemployment
rate has risen by nearly two percent. As these numbers climb,
more and more Americans are losing their employer-based insurance
and are joining the ranks of the uninsured.
America’s pharmaceutical research companies strongly
support efforts to assure that all Americans have access to
high-quality, affordable health insurance coverage. We support
building on the employer-based system while expanding health
insurance coverage through a public-private approach.
To that end, we support a number of initiatives to expand
private health insurance as a way to reduce the number of
uninsured and expand access to private insurance – such
as tax credits aimed at low-wage, small businesses, subsidies
for low- and moderate-income families to obtain private coverage,
and creating new pooling arrangements and insurance reforms
that will enable those with pre-existing conditions to have
access to more affordable group coverage.
We believe providing individuals and families with a choice
among competing private plans holds promise toward delivering
a healthcare system that improves both affordability and access
for uninsured and under-insured Americans.
Moreover, we also recognize the important role that public
programs – like Medicaid and the State Children’s
Health Insurance Program - play as a safety net for the most
vulnerable and strongly believe these programs can play an
important role in reducing the number of uninsured by filling
gaps in coverage.
PhRMA is also proud to support reauthorization of the SCHIP
- with a focus on covering more uninsured children and improving
outreach and enrollment in the program.
Improving our healthcare system will require more than enhanced
access to insurance. Comprehensive health system reforms –
such as improving chronic disease prevention – are also
necessary to improving affordability, quality and value.
Chronic diseases are the number one cause of death and disability
in the U.S., according to the Centers for Disease Control
and Prevention (CDC). Nearly half of all Americans suffer
from at least one chronic disease, and many of these diseases
– such as cancer and diabetes – disproportionally
impact the African American community.
We need to eliminate this disparity not just through improved
access to care, but also through prevention initiatives, reduction
of communication barriers and expansion of support for African
Americans seeking to become doctors, nurses or other healthcare
providers.
Now more than ever, healthcare services like the Partnership
for Prescription Assistance (PPA) are an important lifeline
to patients coping with chronic disease and financial hardship.
The PPA is a nationwide effort, sponsored by America’s
pharmaceutical research and biotechnology companies, to raise
awareness of patient assistance programs and the need to halt
the alarming rise in chronic disease rates.
The PPA has helped more than five million patients nationwide
since its launch in April 2005.
A one-stop clearinghouse, the PPA provides information on
more than 475 patient assistance programs, including nearly
200 programs sponsored by pharmaceutical companies. Patients
can visit PPA’s easy-to-use website (www.pparx.org)
or call the toll-free phone number (1-888-4PPA-NOW), where
trained operators field calls in 150 languages.
America’s pharmaceutical research companies look forward
to working with Barack Obama and his Administration, as well
as leaders in Congress, to tackle our nation’s healthcare
challenges in 2009 and beyond.
Larry Lucas is a vice president for the Pharmaceutical
Research and Manufacturers of America (PhRMA).
|